PTGX — Protagonist Therapeutics Share News
0.000.00%
Last trade - 00:00- $8.84bn
- $8.05bn
- $46.02m
Protagonist Therapeutics surges after media reports J&J in talks to buy co
Johnson & Johnson in talks to acquire Protagonist Therapeutics, WSJ reports (updated)
Johnson & Johnson in talks to acquire Protagonist Therapeutics, WSJ reports
Brief: Johnson & Johnson In Talks To Buy Protagonist Therapeutics - WSJ
U.S. RESEARCH ROUNDUP-Carvana, Marvell Technology, Wayfair
Protagonist Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Protagonist Therapeutics Q2 net loss beats expectations
Protagonist Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Protagonist Therapeutics Inc expected to post a loss of 17 cents a share - Earnings Preview
Brief: Protagonist Therapeutics Takeda To Lead Regulatory Strategy For Rusfertide In Polycythemia Vera NDA
U.S. STOCKS ON THE MOVE-Veren, CME Group, Cognizant
U.S. STOCKS ON THE MOVE-Willis Lease Finance, CME Group
Protagonist Therapeutics rises as bowel disease drug succeeds mid-stage study
U.S. RESEARCH ROUNDUP-California Resources, Eli Lilly, Mastec
U.S. STOCKS ON THE MOVE-THOR Industries, TG Therapeutics, Target
U.S. STOCKS ON THE MOVE-Melco Resorts, Chipotle, Allegro
U.S. STOCKS ON THE MOVE-Tesla, SolarEdge ,Protagonist
Protagonist climbs as blood cancer treatment succeeds late-stage study
Brief: Protagonist And Takeda Announce Positive Topline Results From Phase 3 Verify Study Of Rusfertide